<DOC>
	<DOC>NCT01242774</DOC>
	<brief_summary>This study will be conducted to assess the maximum tolerated dose (MTD) of panobinostat given 3 times a week (administered on weeks 2 and 3 of a 4 week cycle) in combination with induction chemotherapy (idarubicin and cytarabine) in newly diagnosed patients with a cytopathologically confirmed diagnosis of high-risk AML, and to investigate the safety of the combination in this regimen.</brief_summary>
	<brief_title>Safety &amp; Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients &lt; 65 Years Old With Acute Myeloid Leukemia (AML)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Newly diagnosed adult patients = 65 years old with a cytopathologically confirmed diagnosis of highrisk AML = 20% bone marrow blasts via bone marrow aspiration or biopsy The patient has not yet been treated for AML 1ยบ or 2ยบ AML patients with highrisk category features ECOG PS = 2 Renal function and liver function limits. Patient with a 'favorable' or 'betterrisk' cytogenetic profile = t(15;17); t(8;21); or inv(16) or t(16;16) Patient has clinical symptoms suggestive of CNS leukemia and/or CSF findings for CNS leukemia Prior treatment with deacetylase inhibitors (DACi) including, panobinostat Impaired cardiac function Female patient who is pregnant or breast feeding Male patient who is not willing to use a barrier method of contraception Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>AML</keyword>
	<keyword>bone marrow</keyword>
	<keyword>abnormal blast cells of myeloid</keyword>
	<keyword>acute leukemia</keyword>
	<keyword>cytogenetic abnormalities</keyword>
	<keyword>HDACi</keyword>
</DOC>